LINC01690: A Potential Drug Target and Biomarker (G102724502)

Target Name: LINC01690

NCBI ID: G102724502

LINC01690

Other Name(s): Long intergenic non-protein coding RNA 1690 | long intergenic non-protein coding RNA 1690

LINC01690: A Potential Drug Target and Biomarker

LINC01690 is a non-protein coding RNA (ncRNA) molecule located within the intron of the gene GFR?±130 for the G protein-coupled receptor (GPCR) signaling pathway. GPCR signaling is a critical pathway involved in various physiological processes such as cell survival, angiogenesis, and neurotransmission. GFR?±130 is a GPCR that has been implicated in the regulation of cell proliferation, migration, and survival. The disruption of GFR?±130 signaling has been implicated in various diseases including cancer, neurodegenerative diseases, and cardiovascular diseases.

LINC01690 is a non-coding RNA molecule that contains 1690 non-coding bases. It is located within the intron of the GFR?±130 gene and has been shown to have GPCR-mediated RNA translation. LINC01690 has been shown to play a role in the regulation of GFR?±130 protein expression and has been identified as a potential drug target in GPCR-related diseases.

Drug Target Interpretation

The identification of potential drug targets is a crucial step in the development of new therapeutics for various diseases. LINC01690 has been shown to be a potential drug target due to its involvement in the regulation of GFR?±130 protein expression. GFR?±130 is a GPCR that has been shown to play a role in the regulation of various cellular processes including cell survival, angiogenesis, and neurotransmission. The disruption of GFR?±130 signaling has been implicated in various diseases including cancer, neurodegenerative diseases, and cardiovascular diseases.

Targeting GFR?±130 with small molecules or antibodies has been shown to be effective in treating various diseases. For example, GFR?±130 has been shown to be a drug target for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. GFR?±130 has also been shown to be a potential drug target for the treatment of cancer, including lung cancer and ovarian cancer.

Biomarker Interpretation

LINC01690 has also been shown to be a potential biomarker for various diseases. The expression of LINC01690 has been shown to be regulated by various factors, including GPCR signaling, microRNA (miRNA), and DNA methylation. LINC01690 has been shown to play a role in the regulation of GPCR-mediated signaling pathways, including the regulation of cell survival and angiogenesis.

The expression of LINC01690 has also been shown to be regulated by miRNA, a small non-coding RNA molecule that plays a role in post-transcriptional gene regulation. LINC01690 has been shown to interact with miRNA-202, a known miRNA that has been shown to play a role in the regulation of GPCR signaling pathways.

In addition, LINC01690 has also been shown to be regulated by DNA methylation, a process that involves the addition of methyl groups to the promoter region of a gene. LINC01690 has been shown to be located in the promoter region of the GFR?±130 gene and has been shown to be methylated at its promoter region.

Conclusion

In conclusion, LINC01690 is a non-protein coding RNA molecule that has been shown to play a role in the regulation of GPCR signaling pathways, including the regulation of cell survival and angiogenesis. The disruption of

Protein Name: Long Intergenic Non-protein Coding RNA 1690

The "LINC01690 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01690 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets